A brisk walk or bike ride each day can beat breast cancer, study reveals
A BRISK walk or cycle ride every day boosts women's chances of surviving the deadliest breast cancers by almost 70 percent.
Publication date: Available online 31 May 2020Source: Pharmacology &TherapeuticsAuthor(s): Kevin M. Levine, Kai Ding, Lyuqin Chen, Steffi Oesterreich
Publication date: August 2020Source: Biomedicine &Pharmacotherapy, Volume 128Author(s): Qi Chen, Huachao Xu, Jiang Zhu, Kehai Feng, Changlu Hu
Publication date: Available online 30 May 2020Source: PhytomedicineAuthor(s): Weihuan Huang, Yeyin Liang, Hau Yin Chung, Guocai Wang, Jim Junhui Huang, Yaolan Li
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News
In conclusion, the findings of the present study suggest that SSD may induce apoptosis and block autophagic degradation, which provides further evidence of the association between the inhibition of autophagic degradation and cell death. PMID: 32468000 [PubMed - as supplied by publisher]
Series Type : Non-coding RNA profiling by array ; Expression profiling by arrayOrganism : Homo sapiensThis SuperSeries is composed of the SubSeries listed below.
Contributor : Nehad M AlajezSeries Type : Non-coding RNA profiling by arrayOrganism : Homo sapiensExtracted total RNA from FFPE tissue were used for RNA labeling and hybridization on to the Agilent Human SurePrint 8 × 60k v16 miRNA microarray chip according to the manufacturer's protocol.
Contributors : Liu Yuan ; Zhu ZhouSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensA large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to letrozoleCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant activity in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer. Further biomarkers to refine the population beyond ER+/HER2- that benefits remain to be identified. We performed a comprehensive biomarker analysis using patient ...
Contributors : Hee-Joo Choi ; Mi K Park ; Gu KongSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensRNA-sequencing analysis of control and SMYD3-overexpressed MCF7 cell lines. SMYD3 (also known as KMT3E), a hisone H3 lysine K4 methyltransferase, is highly expressed in several human cancers, including colorectal and breast carcinomas. Results provide insight into the transcriptional regulation of SMYD3 in breast cancer.
Contributors : Kiyotsugu Yoshida ; Satomi YogosawaSeries Type : Expression profiling by arrayOrganism : Homo sapiensiRFP713-lebeled iCSCL-10A cells were injected into immunodeficient mice. 5 weeks later, bone metastasized iCSCL-10A cells were extracted from bone marrow was compared with injected cell in vitro culture by microarray and pathway analysis.